Now, with a pipeline chock-full of numerous incretin therapies, the Big Pharma's new strategy will be to test some of those drugs across neurology and immunology indications. "A new focus area ...

We aimed to investigate whether the reduced incretin effect observed in patients with type 2 diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the diabetic state.